Welcome to Teva’s Allegro Clinical Trial Web Site

Allegro is a global research study designed to explore the efficacy and tolerability of an experimental medicine, laquinimod, which is currently in development as a once-daily oral treatment for relapsing-remitting multiple sclerosis (RRMS). The objective of the study is to determine if laquinimod is safe and effective in reducing the number of relapses experienced by RRMS patients.

As study sponsor, Teva Neuroscience is looking for people between the ages of 18 and 55, who have a confirmed diagnosis of RRMS,
to participate in the Allegro study. Our goal is to match interested volunteers with participating research facilities.

Information and Support

To request additional information
about the Allegro study please call

1-866-550-0614
Mon - Fri, 8 - 5 CT

About the Study

The protocol for the Allegro study was developed by a team of neurologists and statisticians from Teva Neuroscience. The study follows the successful conclusion of a second Phase II study. The protocol for the Allegro study has been reviewed and approved by the institutional review boards at each of the study sites.

To learn more visit: www.clinicaltrials.gov see: NCT00509145 or call 1-866-550-0614.

Where can I get more information on RRMS?
www.nationalmssociety.org
www.msif.org